News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx to Present at the Cowen and Company 37th Annual Health Care Conference
MOUNTAIN VIEW, Calif. , Feb. 28, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 10:00 a.m. ET .
View HTML
Toggle Summary Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases
-- ChemoCentryx retains all rights in the United States and China ; Vifor Pharma gains additional marketing rights in Asia , including Japan and Middle Eastern markets -- -- ChemoCentryx to receive additional USD 20 million upfront cash commitment plus royalties on potential net sales --  --
View HTML
Toggle Summary ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer
Company Reports at ASCO 2017 Gastrointestinal Cancers Symposium 24 Week Progression-Free Survival and 48 Week Overall Survival Data as it Continues to Follow Progress in Study Patients
View HTML
Toggle Summary ChemoCentryx Provides Corporate Update Including Development Strategy for Lead Programs in Rare Renal Diseases
-- Company Initiates Phase III "ADVOCATE" Clinical Trial for Complement Receptor Inhibitor Avacopan in ANCA Vasculitis; Development Path Outlined in Rare Kidney Disease for Chemokine Receptor Inhibitor ‘CCX140' -- MOUNTAIN VIEW, Calif. , Jan. 09, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
View HTML
Toggle Summary ChemoCentryx to Present at the 35th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif. , Jan. 04, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the 35 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 12:00 p.m. PT .
View HTML
Toggle Summary Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases
- ChemoCentryx to retain commercialization rights in the United States and China , Vifor Pharma gains rights in all other markets - - ChemoCentryx to receive upfront cash commitment of USD 50 million plus potential milestones and royalties - - Vifor Pharma receives an option to develop and
View HTML
Toggle Summary ChemoCentryx Reports Third Quarter 2016 Financial Results and Provides Corporate Update
-- Preparing for the Initiation of Phase III Development with Complement 5a Receptor Inhibitor Avacopan (CCX168) for the Treatment of ANCA Vasculitis -- -- Reported Positive Data from Ongoing Pilot Phase II Trial of Avacopan in Patients with Atypical Hemolytic Uremic Syndrome -- -- Highlighted
View HTML
Toggle Summary ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (‘CLEAR' and ‘CLASSIC') of Orally Administered Complement 5a Receptor Inhibitor CCX168 (‘Avacopan')
-- Oral presentation at the American Society of Nephrology (ASN) Kidney Week 2016 to highlight Phase II AAV CLEAR trial results -- -- Oral presentation at the American College of Rheumatology (ACR) 2016 Annual Meeting to highlight Phase II AAV CLASSIC trial results -- MOUNTAIN VIEW, Calif. , Nov.
View HTML
Toggle Summary ChemoCentryx to Hold Third Quarter 2016 Financial Results Conference Call on Monday, November 7, 2016
MOUNTAIN VIEW, Calif. , Oct. 28, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's third quarter 2016 financial results will be released after market close on Monday, November 7, 2016 . ChemoCentryx executive management will host a conference call
View HTML
Toggle Summary ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy
Kidney transplant patient treated under a "Special Needs" protocol for previously intractable C3G disease is stable after avacopan treatment; avacopan now continued for more than 13 months
View HTML